STOCK TITAN

Ampio Pharmaceuticals Inc - AMPE STOCK NEWS

Welcome to our dedicated news page for Ampio Pharmaceuticals (Ticker: AMPE), a resource for investors and traders seeking the latest updates and insights on Ampio Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ampio Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ampio Pharmaceuticals's position in the market.

Rhea-AI Summary
Ampio Pharmaceuticals, Inc. announced the receipt of an unqualified audit opinion with a going concern explanation in its Annual Report for 2023. The audit opinion does not alter the financial statements or the Form 10-K. This announcement complies with NYSE American requirements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.15%
Tags
none
-
Rhea-AI Summary
Ampio Pharmaceuticals, Inc. (AMPE) has decided to voluntarily delist its common stock from NYSE American and deregister its stock to terminate reporting obligations under the Exchange Act. The company notified NYSE American of this decision and plans to file a Form 25 with the SEC for delisting and deregistration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-51.7%
Tags
none
-
Rhea-AI Summary
Ampio Pharmaceuticals, Inc. announced the results of nonclinical pre-IND studies for its osteoarthritis treatment, OA-201. The data did not support an IND submission as initially planned due to lack of significant pain reduction benefits compared to previous studies. The company is evaluating future options and implementing cost-saving measures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.69%
Tags
none
Rhea-AI Summary
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced settlements in the pending securities fraud class action and consolidated derivative actions, subject to various conditions. The settlements are supported by the plaintiff in the pending Colorado state court derivative action and two stockholders. The company expects the amount to be covered by its D&O insurance policy. The settlements do not constitute any admission of fault, wrongdoing, or liability. The company aims to finalize and execute the settlement agreements within the next 120 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.61%
Tags
none
-
Rhea-AI Summary
Ampio Pharmaceuticals, Inc. announced that its CEO, Michael A. Martino, will present in the Emerging Growth Conference on November 2, 2023. The conference will focus on the development of a potential treatment for osteoarthritis as part of Ampio's OA-201 program. Investors can register and receive conference updates through the provided link.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
conferences acquisition
-
Rhea-AI Summary
Ampio Pharmaceuticals has selected Ascendia Pharmaceuticals to support the clinical development of its potential treatment for osteoarthritis, OA-201. Ascendia will provide services including formulation development and manufacturing. Ampio was advised by Bruder Consulting & Venture Group throughout the process.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.37%
Tags
Rhea-AI Summary
Ampio Pharmaceuticals CEO to present at Emerging Growth Conference on October 5, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.81%
Tags
conferences acquisition
-
Rhea-AI Summary
Ampio Pharmaceuticals has announced a 20-to-1 reverse stock split of its common stock, which will be effective on September 11, 2023. The stock is expected to begin trading on a split-adjusted basis on September 12, 2023. The reverse stock split was approved by stockholders at the Company's Annual Meeting. The Company does not expect the reverse stock split to impact its business operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.11%
Tags
none
-
Rhea-AI Summary
Ampio Pharmaceuticals declares dividend of Series D Preferred Stock to common stock holders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
dividends
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25%
Tags
none
Ampio Pharmaceuticals Inc

NYSE:AMPE

AMPE Rankings

AMPE Stock Data

340.61k
1.12M
1.56%
4.19%
2.9%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Englewood

About AMPE

ampio pharmaceuticals inc (ampe) is a biotechnology company located in 5445 dtc pkwy, greenwood village, colorado, united states.